ABT-263, a BCL-2 inhibitor, selectively eliminates latently HIV-1-infected cells without viral reactivation.
Human immunodeficiency virus-1 (HIV-1) is a hazardous pathogen responsible for causing acquired immunodeficiency syndrome (AIDS). HIV-1 provirus survives in latently infected cells for a long time, despite treatment with combinational anti-retroviral therapy (cART); therefore, it is considered as a...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2025-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://doi.org/10.1371/journal.pone.0322962 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|